Huang Chienhsiu
Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Min-Sheng Road, Dalin Town, Chiayi County 622401, Taiwan.
Medicina (Kaunas). 2025 Jun 30;61(7):1197. doi: 10.3390/medicina61071197.
Infections with species are rare, and the susceptibility patterns of these species to antimicrobial agents are unclear. Therefore, the aim of this study was to explore the clinical and epidemiological features and antimicrobial susceptibility patterns of species by reviewing previous research on the antibiograms of species and the illnesses caused by species. A comprehensive search of the PubMed and Web of Science databases was conducted for all studies that investigated antimicrobial susceptibility patterns of species published between January 1990 and February 2025. An extensive review of the infection incidences, isolation sites, clinical characteristics, and antimicrobial susceptibility patterns for infections caused by species was performed. Several studies have revealed that the incidence of species infections is increasing, particularly in patients with comorbid conditions, mainly cardiovascular disease, diabetes mellitus, and malignancy. Most patients were elderly individuals, and most related illnesses were acquired in hospitals. The number of patients who received inappropriate antimicrobial therapy outnumbered the number of those who died. Antibiotics had little effect on species infection outcomes. Sixteen studies were included in the current scoping review. The susceptibility rates of to piperacillin/tazobactam (2.9-100%), ciprofloxacin (4.34-85%), levofloxacin (8.69-100%), trimethoprim/sulfamethoxazole (33.3-100%), imipenem (0-33.3%), meropenem (0-38.8%), minocycline (30.4-100%), ceftazidime (0-100%), and cefepime (0-100%) varied. The susceptibility rates of to piperacillin/tazobactam (0-33%), ciprofloxacin (21.4-40%), levofloxacin (59.5%), trimethoprim/sulfamethoxazole (57.1-93.3%), imipenem (0-2.4%), meropenem (0%), minocycline (83.3-100%), ceftazidime (0-23.8%), and cefepime (0-19.0%) varied. Morbidity and mortality due to the increasing incidence of species infections have considerably increased. Underlying immunological defenses and other clinical factors may influence the prognosis of species infection. Rather than bacterial virulence characteristics, host factors mostly affect patient outcomes. Most isolates of are susceptible to minocycline and trimethoprim/sulfamethoxazole. For the treatment of these infections, professional knowledge and therapeutic expertise must be integrated.
感染该菌种的情况较为罕见,且这些菌种对抗菌药物的敏感性模式尚不清楚。因此,本研究的目的是通过回顾以往关于该菌种抗菌谱及由该菌种引起的疾病的研究,探讨该菌种的临床和流行病学特征以及抗菌药物敏感性模式。对PubMed和Web of Science数据库进行了全面检索,查找1990年1月至2025年2月间发表的所有调查该菌种抗菌药物敏感性模式的研究。对该菌种引起的感染的发病率、分离部位、临床特征和抗菌药物敏感性模式进行了广泛综述。多项研究表明,该菌种感染的发病率在上升,尤其是在患有合并症的患者中,主要是心血管疾病、糖尿病和恶性肿瘤患者。大多数患者为老年人,且大多数相关疾病是在医院获得的。接受不适当抗菌治疗的患者数量超过死亡患者数量。抗生素对该菌种感染的治疗效果甚微。本综述纳入了16项研究。该菌种对哌拉西林/他唑巴坦(2.9 - 100%)、环丙沙星(4.34 - 85%)、左氧氟沙星(8.69 - 100%)、复方磺胺甲恶唑(33.3 - 100%)、亚胺培南(0 - 33.3%)、美罗培南(0 - 38.8%)、米诺环素(30.4 - 100%)、头孢他啶(0 - 100%)和头孢吡肟(0 - 100%)的敏感率各不相同。另一种该菌种对哌拉西林/他唑巴坦(0 - 33%)、环丙沙星(21.4 - 40%)、左氧氟沙星(59.5%)、复方磺胺甲恶唑(57.1 - 93.3%)、亚胺培南(0 - 2.4%)、美罗培南(0%)、米诺环素(83.3 - 100%)、头孢他啶(0 - 23.8%)和头孢吡肟(0 - 19.0%)的敏感率也各不相同。由于该菌种感染发病率上升导致的发病率和死亡率大幅增加。潜在的免疫防御和其他临床因素可能影响该菌种感染的预后。影响患者预后的主要是宿主因素,而非细菌毒力特征。该菌种的大多数分离株对米诺环素和复方磺胺甲恶唑敏感。对于这些感染的治疗,必须综合专业知识和治疗专长。